In general, ALM seems to respond to anti-PD1 therapy, more specifically with combination therapy regimens, typically including anti-PD1 therapy with anti-CTLA4 therapy but at a lower frequency than when used for cutaneous melanomas (49, 50, 52, 53, 55–57, 60–62). Here, CTLA4 is linked to acral lentiginous melanoma.